Dual-drug microneedle patch targets inflammation and fat browning

The worldwide weight problems disaster has develop into a dominant public well being disaster throughout the globe. Over 3 billion folks worldwide presently undergo from weight problems, and forecasts warn the quantity will rise above 4 billion by 2035, accounting for greater than half the worldwide inhabitants. As a significant non-communicable illness, weight problems triggers persistent visceral adipose irritation and drastically raises dangers of kind 2 diabetes, cardiovascular sicknesses, metabolic fatty liver illness and varied cancers.

Semaglutide, a mainstream GLP-1 agonist authorised for weight reduction, suppresses urge for food by activating central hypothalamic GLP-1 receptors to manage systemic power stability. Regardless of its dependable weight-lowering efficiency, the drug’s brain-centered mechanism results in speedy weight regain as soon as therapy stops, which severely limits long-term metabolic advantages. Researchers have tried to pair semaglutide with adipose-targeted browning compounds to spice up fats power consumption, but continual inflammatory adipose microenvironments block thermogenic gene expression and weaken such therapeutic results.

New analysis reveals an missed peripheral immunomodulatory property of semaglutide. Aside from its central appetite-regulating operate, semaglutide binds GLP-1 receptors on adipose macrophages and drives their shift from pro-inflammatory M1 to anti-inflammatory M2 subtypes, easing native adipose inflammation. This discovering impressed the crew to design a synergistic dual-drug remedy pairing semaglutide with rosiglitazone, a PPAR-γ agonist that stimulates white fats browning.

To comprehend localized, sustained co-delivery of the 2 brokers, scientists developed an adipose-targeted composite microneedle patch named LRSG-SG@MN. Tuned from hyaluronic acid, gelatin and gelatinized starch, the microneedles possess favorable mechanical power and sluggish degradation charges. Nano-lipid nanoparticles carrying rosiglitazone and semaglutide are embedded inside the patch to attain long-term drug launch in subcutaneous fats tissue.

As soon as utilized, semaglutide remodels the immune panorama of fats tissue by assuaging irritation and adipocyte oxidative stress, creating supportive situations for fats browning. In the meantime, lipid nanocarriers selectively ship rosiglitazone into adipocytes to activate PPAR-γ signaling and speed up thermogenic browning of white fats. The 2 medicine work synergistically to beat the 2 core drawbacks of single-agent weight problems remedies: post-treatment weight rebound and inflammation-suppressed fats browning.

In high-fat diet-induced overweight mouse fashions, the microneedle system achieves potent weight discount, relieves glucolipid metabolic problems and avoids vital weight rebound after therapy withdrawal, with passable biosafety efficiency. This adipose-targeted long-acting microneedle platform integrates immune regulation and fats browning induction, providing a translational dual-mechanism technique for sustainable scientific weight problems intervention.

Different contributors embody Weiqin Yao, Jiawen Wang, Xuan Zeng, Weihai Chen from Wuhan College.

This work was supported by the Nationwide Pure Science Basis of China (Nos. 52273148, 52333004, and 52473145).